Date: 06/08/2026
Transaction Details
Morepen RX Limited (MRX), a wholly owned subsidiary of Morepen Laboratories Limited, allotted 2,00,00,000 (Two Crore) equity shares of ₹10 each at par to Morepen Laboratories Limited. The total consideration for the allotment is ₹20,00,00,000 (Rupees Twenty Crores Only). This allotment was made pursuant to a rights issue by MRX.
The Finance Committee of the Board of Directors of Morepen Laboratories Limited took note of this allotment at its meeting held on 6th August 2026.
Post-Allotment Shareholding
Consequent to this allotment, Morepen Laboratories Limited's shareholding in MRX has increased to 2,70,82,356 (Two Crore Seventy Lakh Eighty-Two Thousand Three Hundred Fifty-Six) equity shares. MRX continues to remain a wholly owned subsidiary of the company.
Target Entity Details
Name: Morepen RX Limited (MRX)
Industry: Pharmaceutical
Incorporation Date: 17th March 2023
Business: Sales and marketing of Branded Prescription ("Rx") products, primarily operating in India.
Financial Performance (Turnover):
- FY 2025-26: ₹5,449.84 Lakh
- FY 2024-25: ₹11,276.35 Lakh
- FY 2023-24: ₹8,383.45 Lakh
Net Worth (as of 31st March 2026): ₹47.72 Lakh (based on audited financial statements)
Related Party Transaction
This acquisition falls within related party transactions as MRX is a wholly owned subsidiary. Mr. Sanjay Suri, Mr. Varun Suri, and Ms. Shalu Suri (members of the promoter group of Morepen Laboratories Limited) are also Directors of MRX. Except for this relationship, no other promoter, promoter group, or group companies have any interest in MRX.
Objects and Impact
The subscription to the rights issue of MRX was undertaken to strengthen its capital base and support its business operations.
Consideration and Approval
The consideration for the acquisition was paid in cash. No governmental or regulatory approvals were required for this acquisition.